Keeping Track: Incomplete Responses For Unusual Times; Qtrypta Is Latest CRL

Highlights from complete response letter news from the Pink Sheet’s US FDA Performance Tracker.

Keeping Track Feature image

The difficulties of conducting manufacturing inspections and review activities in the COVID-19 era seems to be encouraging the FDA to find a response that is less definitive than a complete response letter and less formal than a user fee goal date extension.

Spectrum Pharmaceuticals Inc. became the latest recipient of a “not a complete response” letter upon the 24 October 2020...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers